Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?
Parliament Will Scrutinize Deal On Saturday
Executive Summary
Industry would settle for UK Prime Minister Boris Johnson’s deal, with sweeteners promised for the sector
You may also be interested in...
UK Signs First No-Deal Brexit Ferry Contracts
If the UK leaves the EU without a deal at the end of this month, pharmaceutical companies will be able to book space for medicine deliveries on ferries run by four operators between UK and EU ports.
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.